Genotype-specific MRD interpretation improves stratification in paediatric acute lymphoblastic leukaemia

מידע ביבליוגרפי
Main Authors:	O'Connor, D, Enshaei, A, Bartram, J, Hancock, J, Harrison, C, Hough, R, Samarasinghe, S, Schwab, C, Vora, A, Wade, R, Moppett, J, Moorman, A, Goulden, N
פורמט:	Journal article
יצא לאור:	American Society of Clinical Oncology 2017

Cytogenetic-specific heterogeneity in the kinetics of minimal residual disease (MRD) clearance in childhood acute lymphoblastic leukaemia (ALL)
מאת: Moorman, A, et al.
יצא לאור: (2007)

Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia.
מאת: O'Connor, D, et al.
יצא לאור: (2017)

A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia.
מאת: Moorman, A, et al.
יצא לאור: (2014)

Post-Remission MRD Kinetics in Children with Acute Lymphoblastic Leukaemia Receiving Augmented BFM Consolidation Compared with Other Regimens Results of the Medical Research Council Trial UKALL2003.
מאת: Cutting, R, et al.
יצא לאור: (2008)

Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol.
מאת: Patrick, K, et al.
יצא לאור: (2014)

Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol
מאת: Patrick, K, et al.
יצא לאור: (2014)

Delineation of Risk Factors in Paediatric Acute Lymphoblastic Leukaemia with Favourable Cytogenetics
מאת: Moorman, A, et al.
יצא לאור: (2012)

Post-remission MRD kinetics in children with acute lymphoblastic leukaemia receiving augmented BFM consolidation compared with other regimens: update of results of the Medical Research Council Trial UKALL2003
מאת: Cutting, R, et al.
יצא לאור: (2009)

Cytogenetic-specific heterogeneity in the kinetics of minimal residual disease (MIRD) clearance in childhood lymphoblastic leukaemia (ALL)
מאת: Moorman, A, et al.
יצא לאור: (2008)

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
מאת: Vora, A, et al.
יצא לאור: (2014)

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): A randomised controlled trial
מאת: Vora, A, et al.
יצא לאור: (2014)

Down Syndrome is a significant risk factor for infectious deaths in childhood acute lymphoblastic leukaemia: a retrospective analysis of the infectious deaths on UKALL 2003
מאת: O'Connor, D, et al.
יצא לאור: (2014)

Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003
מאת: Patrick, K, et al.
יצא לאור: (2014)

Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.
מאת: Patrick, K, et al.
יצא לאור: (2014)

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
מאת: Vora, A, et al.
יצא לאור: (2013)

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial
מאת: Vora, A, et al.
יצא לאור: (2013)

Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003
מאת: Samarasinghe, S, et al.
יצא לאור: (2013)

Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.
מאת: Samarasinghe, S, et al.
יצא לאור: (2013)

PCR-based MRD testing for acute lymphoblastic leukaemia in India
מאת: Rubina Islam, et al.
יצא לאור: (2017-01-01)

Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003.
מאת: O'Connor, D, et al.
יצא לאור: (2014)

Comparison of clinical significance of MRD as determined by IgH genescanning or allele specific probing in childhood ALL.
מאת: Moppett, J, et al.
יצא לאור: (2002)

Profile of Steroid Toxicity During Maintenance Treatment in Teenage and Young Adult (TYA) Patients with Acute Lymphoblastic Leukaemia (ALL)
מאת: Tomlins, J, et al.
יצא לאור: (2012)

Improved Outcome for Children and Young Adults with T-Cell Acute Lymphoblastic Leukaemia (ALL): Results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003
מאת: Vora, A, et al.
יצא לאור: (2008)

Efficacy and Toxicity of Pegylated Asparaginase in the Treatment of Children and Young Adults with Acute Lymphoblastic Leukaemia: Results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003
מאת: Vora, A, et al.
יצא לאור: (2008)

Incidence and Outcome of Osteonecrosis in Children and Young Adults with Acute Lymphoblastic Leukaemia Treated on a Dexamethasone Containing Protocol: Results of the Medical Research Council UK Trial ALL 2003
מאת: Vora, A, et al.
יצא לאור: (2008)

Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials.
מאת: Moorman, A, et al.
יצא לאור: (2013)

The impact of risk stratification by early bone-marrow response in childhood lymphoblastic leukaemia: results from the United Kingdom Medical Research Council trial ALL97 and ALL97/99.
מאת: Mitchell, C, et al.
יצא לאור: (2009)

Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials.
מאת: Ramanujachar, R, et al.
יצא לאור: (2007)

Late relapsing childhood lymphoblastic leukaemia.
מאת: Frost, L, et al.
יצא לאור: (1997)

UKALL 2003, A Randomised Trial Investigating Treatment Reduction for Children and Young Adults with Minimal Residual Disease Defined Low Risk Acute Lymphoblastic Leukaemia
מאת: Vora, A, et al.
יצא לאור: (2010)

PROSPECTIVE EVALUATION OF QUALITY OF LIFE (QOL) IN CHILDREN TREATED IN UKALL 2003 FOR ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL): A COHORT STUDY
מאת: Eiser, C, et al.
יצא לאור: (2012)

Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia.
מאת: Harrison, C, et al.
יצא לאור: (2004)

Late relapsing childhood acute lymphoblastic leukaemia.
מאת: Frost, L, et al.
יצא לאור: (1998)

Intraocular relapse of childhood acute lymphoblastic leukaemia.
מאת: Somervaille, T, et al.
יצא לאור: (2003)

Variables affecting kinetics of minimal residual disease clearance in children with lymphoblastic leukaemia; Results of the United Kingdom Medical Research Council (UK MRC) protocols ALL97, ALL97/99 and ALL2003.
מאת: Vora, A, et al.
יצא לאור: (2005)

Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.
מאת: Lennard, L, et al.
יצא לאור: (2013)

Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987-1999.
מאת: Chessells, J, et al.
יצא לאור: (2002)

Molecular mechanisms involved in chemoresistance in paediatric acute lymphoblastic leukaemia
מאת: Stanković Tatjana, et al.
יצא לאור: (2008-01-01)

Genotype-specific MRD interpretation improves stratification in paediatric acute lymphoblastic leukaemia

פריטים דומים

פריטים דומים